UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2011

 

 

COMPLETE GENOMICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34939   20-3226545

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

2071 Stierlin Court

Mountain View, California 94043

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 943-2800

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 22, 2011, Complete Genomics, Inc. (the “Company”) held its annual meeting of stockholders at its facility in Mountain View, California. The stockholders of the Company voted on the four proposals listed below. The final results for the votes regarding each proposal are set forth below. The proposals are described in detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on May 2, 2011.

1. Elect three Class I members of the Board of Directors to serve for a three-year term until the 2014 Annual Meeting of Stockholders or until their respective successors are elected and qualified or their earlier resignation or removal:

 

Name

   Votes
For
     Withheld      Abstentions      Broker
Non-Votes
 

Carl L. Gordon, Ph.D., CFA

     21,057,239         40,549         —           1,116,208   

Lewis J. Shuster

     21,039,108         58,680         —           1,116,208   

Charles P. Waite, Jr.

     21,043,326         54,462         —           1,116,208   

2. Advisory vote on executive compensation.

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

20,574,753

  493,359   29,676   1,116,208

3. Advisory vote on the frequency of the advisory vote on executive compensation.

 

1 Year

 

2 Years

 

3 Years

 

Abstentions

3,877,575

  5,948   17,183,974   30,291

4. Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2011.

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

22,072,949

  16,034   125,013  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 27, 2011     COMPLETE GENOMICS, INC.
    By:  

/s/ Ajay Bansal

    Name: Ajay Bansal
    Title: Chief Financial Officer